![Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. - Abstract - Europe PMC Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7088950/bin/pt9b00060_0005.jpg)
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. - Abstract - Europe PMC
![Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d2559d810755846583092108e375b02a1147ddea/2-Figure1-1.png)
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar
![Therapeutic approaches to CFTR dysfunction: From discovery to drug development - Journal of Cystic Fibrosis Therapeutic approaches to CFTR dysfunction: From discovery to drug development - Journal of Cystic Fibrosis](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/35b1ff8e-bdd1-4a05-b75a-1950c49240f9/gr1_lrg.jpg)
Therapeutic approaches to CFTR dysfunction: From discovery to drug development - Journal of Cystic Fibrosis
![Frontiers | CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine | Pharmacology Frontiers | CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine | Pharmacology](https://www.frontiersin.org/files/MyHome%20Article%20Library/500191/500191_Thumb_400.jpg)
Frontiers | CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine | Pharmacology
![Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers - ScienceDirect Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168365919300525-gr1.jpg)
Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers - ScienceDirect
![Biomolecules | Free Full-Text | Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis Biomolecules | Free Full-Text | Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis](https://www.mdpi.com/biomolecules/biomolecules-11-00422/article_deploy/html/images/biomolecules-11-00422-sch001.png)
Biomolecules | Free Full-Text | Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis
![Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. - Abstract - Europe PMC Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7088950/bin/pt9b00060_0002.jpg)
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. - Abstract - Europe PMC
![A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR | Communications Biology A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR | Communications Biology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs42003-018-0153-0/MediaObjects/42003_2018_153_Fig1_HTML.png)